BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20962476)

  • 1. [Treatment of myeloproliferative neoplasms].
    Motoji T
    Rinsho Ketsueki; 2010 Oct; 51(10):1428-36. PubMed ID: 20962476
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chronic myeloproliferative diseases. New knowledge about well known diseases].
    Aulitzky WE; Griesshammer M; Heimpel H; Huhn D
    Dtsch Med Wochenschr; 1996 May; 121(18):600-4. PubMed ID: 8625788
    [No Abstract]   [Full Text] [Related]  

  • 3. [Molecular pathophysiology and treatment overview of PV, ET and PMF].
    Komatsu N
    Rinsho Ketsueki; 2012 Oct; 53(10):1589-99. PubMed ID: 23037731
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical predictors of outcome in MPN.
    Passamonti F; Maffioli M; Merli M; Ferrario A; Caramazza D
    Hematol Oncol Clin North Am; 2012 Oct; 26(5):1101-16. PubMed ID: 23009940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myeloproliferative neoplasms in the elderly.
    Maffioli M; Orlandi E; Passamonti F
    Eur J Intern Med; 2018 Dec; 58():33-42. PubMed ID: 29793825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis and therapy of chronic myeloproliferative disorders].
    Kimura A
    Nihon Naika Gakkai Zasshi; 1998 Mar; 87(3):507-12. PubMed ID: 9577584
    [No Abstract]   [Full Text] [Related]  

  • 7. The myelodysplastic syndromes and myeloproliferative disorders.
    Williams JL
    Clin Lab Sci; 2004; 17(4):223-34. PubMed ID: 15559729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for essential thrombocythemia and polycythemia vera.
    Vannucchi AM; Guglielmelli P; Pieri L; Antonioli E; Bosi A
    Expert Rev Hematol; 2009 Feb; 2(1):41-55. PubMed ID: 21082994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloproliferative Neoplasms.
    Spivak JL
    N Engl J Med; 2017 Jun; 376(22):2168-2181. PubMed ID: 28564565
    [No Abstract]   [Full Text] [Related]  

  • 10. The myeloproliferative disorders.
    Gilbert HS; Dameshek W
    Dis Mon; 1970 Oct; ():1-52. PubMed ID: 4921953
    [No Abstract]   [Full Text] [Related]  

  • 11. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The management of elderly patients with myeloproliferative disorders.
    Tura S
    Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract]   [Full Text] [Related]  

  • 13. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases.
    Harrison C
    Br J Haematol; 2005 May; 129(3):293-306. PubMed ID: 15842653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J; Fijnheer R; Walsh IB; Hermans MH
    Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.
    Guglielmelli P; Bartalucci N; Rotunno G; Vannucchi AM
    Expert Rev Hematol; 2014 Aug; 7(4):423-5. PubMed ID: 24849893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The treatment of myeloproliferative syndromes].
    Maurice P
    Schweiz Med Wochenschr; 1975 Oct; 105(40):1269-74. PubMed ID: 1061995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases.
    Guilpain P; Montani D; Damaj G; Achouh L; Lefrère F; Le Pavec J; Marfaing-Koka A; Dartevelle P; Simonneau G; Humbert M; Hermine O
    Respiration; 2008; 76(3):295-302. PubMed ID: 18160817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comprehensive care of patients with thrombocythemia].
    Hrubisková K; Steruská M; Horváth A
    Vnitr Lek; 1987 Oct; 33(10):872-82. PubMed ID: 3479860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.